Inclusion Criteria:

- Male or female > 18 years

- Histologically confirmed solid tumor.

- Subjects who have not received chemotherapy and / or radiotherapy in the last 3
months.

- Subject to initiate a chemotherapy (ie, cycle 1, day 1)

- The chemotherapy regimen should have an inherent risk of febrile neutropenia of
10-20%.

- Planning a minimum of 3 cycles chemotherapy.

- Adequate bone marrow reserve defined by: leukocytes ≥ 3,000 / mm3, platelets ≥
100.000/mm3; neutrophils ≥ 1,500 / mm3.

- Adequate hepatic and renal function, defined by: bilirubin <1.5 times the normal
value, ALT and AST <3 times the normal range (both can be elevated up to 5 times the
normal value in patients with known liver metastases); creatinine <1.5 times upper
normal value

- ECOG ≤ 2.

- Informed consent

Exclusion Criteria:

- Patients under treatment with an investigational treatment.

- Active infection in the last 72 h before starting chemotherapy.

- Indication of chemotherapy dose intensity or chemotherapy included in the risk rating
of febrile neutropenia <10% or >20%.

- Patients with concomitant chemoradiotherapy.

- Patients being treated with biological drugs in monotherapy.

- Any other condition causing neutropenia.

- History of bone marrow transplant or stem cells.